Premium
Pharmacokinetics and pharmacodynamics of a new transdermal delivery system for bopindolol.
Author(s) -
Drewe J.,
Meier R.,
Timonen U.,
Thumshirn M.,
Munzer J.,
Kissel T.,
Gyr K.
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb05591.x
Subject(s) - pharmacokinetics , transdermal , medicine , pharmacodynamics , tolerability , dosing , pharmacology , transdermal patch , anesthesia , adverse effect
1. In two separate studies, each with 12 healthy male volunteers, the pharmacokinetic and dynamic properties of a transdermal delivery system for bopindolol were evaluated. 2. In study I it was shown that bopindolol absorption from a 14 mg patch occurred over the whole 7‐day application period. No signs of a significant skin depot were found. 3. In study II, a linear pharmacokinetic behaviour but a non‐linear kinetic/dynamic relationship was established for the patches over a dose range from 7 to 21 mg. Comparable peak effects of reduction in exercise‐induced tachycardia were observed after different patch doses and an i.v. injection. However, the effect was significantly prolonged with the patches compared with the injection and was maintained over 7 days. 4. The patches showed a good local and systemic tolerability in both studies over a dosing interval of up to 7 days.